BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2021

View Archived Issues

Structure-based multivalent nanobodies neutralize SARS-CoV-2 and prevent viral escape

Read More

FDA clears IND for phase I trial of MT-6402 in PD-L1-positive solid tumors

Read More

FDA accepts C4 Therapeutics' IND for phase I/II trial of CFT-7455 in multiple myeloma and NHL

Read More

Gritstone develops second-generation vaccine against SARS-CoV-2

Read More

First patient dosed in phase I study of FT-7051 in metastatic CRPC

Read More

European Commission approves extension of the indication for Doptelet as treatment of ITP

Read More

Preliminary topline phase II data for NSI-566 in ischemic stroke

Read More

Positive confirmatory data from atopic dermatitis cohort of EDP-1815 phase Ib trial

Read More

Adamis submits IND to the FDA for tempol as treatment of COVID-19

Read More

National University of Singapore, Nanyang Technological University patent RNA editing inhibitors

Read More

New cannabinoid CB1/CB2 receptor ligands presented by Canopy Growth Corp.

Read More

Merck & Co. discovers antituberculosis compounds

Read More

Long-term phase III data for lisdexamfetamine dimesylate in preschool-aged children with ADHD

Read More

Big picture look reveals RNA-binding proteins' role in psychiatric disorders

Read More

Arcutis plans to study roflumilast foam in phase III for seborrheic dermatitis

Read More

12-Week study shows benvitimod cream is efficacious and safe in plaque psoriasis

Read More

FDA approves IND for phase IIa study of JNJ-40411813 in epilepsy

Read More

Inhibitor BAS-2 illuminates role of HDAC6 in glycolytic metabolism in TNBC

Read More

c2H2/c3C1, a two-MAb cocktail with high therapeutic efficacy against SARS-CoV-2 infections

Read More

Tavotek Biotherapeutics presents bispecific antibodies to TNF-alpha, IL-1beta

Read More

Interim phase I data on OTX-TIC in primary open-angle glaucoma or ocular hypertension

Read More

MCB-613 attenuates loss of cardiac function after myocardial infarction

Read More

Thetis completes pre-IND meeting for TP-317 for inflammatory bowel disease

Read More

PK and PD data presented for ADAIR, an IR formulation of dextroamphetamine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing